Apollo Endosurgery, Inc. is a medical technology company founded in 2006 and focused on developing next-generation, less invasive devices for therapeutic endoscopy. Their devices are designed to treat various gastrointestinal conditions, such as closure of defects, managing complications, and treating obesity. Offering products in over 75 countries, the company's innovative therapies, including the OverStitch™ Endoscopic Suturing System and the ORBERA® Intragastric Balloon, provide alternatives to invasive surgical procedures, thus reducing complication rates and healthcare costs. Notably, Apollo Endosurgery recently received a $35.00M post-IPO debt investment from Innovatus Capital Partners on 21 December 2021. This strategic investment marks an exciting phase for the company, reflecting confidence in its potential for growth and innovation in the biotechnology and health care sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $35.00M | 1 |
|
21 Dec 2021 |
| Post-IPO Equity | $65.00M | - | 12 Oct 2021 | |
| Post-IPO Debt | $20.00M | 1 | Craig-Hallum Capital Group | 13 Aug 2019 |
| Post-IPO Equity | $23.70M | - | 22 Jun 2018 | |
| Convertible Note | $22.00M | 1 | PTV Healthcare Capital | 01 Nov 2015 |
No recent news or press coverage available for Apollo Endosurgery.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
